Early mixed T-cell chimerism is predictive of pediatric AML or MDS relapse after hematopoietic stem cell transplant. Pediatr Blood Cancer 2017 Sep;64(9)
Date
03/08/2017Pubmed ID
28266766DOI
10.1002/pbc.26493Scopus ID
2-s2.0-85014674706 (requires institutional sign-in at Scopus site) 8 CitationsAbstract
Patients with acute myeloid leukemia (AML) who relapse after hematopoietic stem cell transplantation (HCT) have dismal outcomes. Our ability to predict those at risk for relapse is limited. We examined chimerism trends post-HCT in 63 children who underwent HCT for AML or myelodysplastic syndrome (MDS). Mixed T-cell chimerism at engraftment and absence of chronic graft versus host disease (cGVHD) were associated with relapse (P = 0.04 and P = 0.02, respectively). Mixed T-cell chimerism at engraftment was predictive in patients without cGVHD (P = 0.03). Patients with engraftment mixed T-cell chimerism may warrant closer disease monitoring and consideration for early intervention.
Author List
Broglie L, Helenowski I, Jennings LJ, Schafernak K, Duerst R, Schneiderman J, Tse W, Kletzel M, Chaudhury SAuthor
Larisa Broglie MD, MS Assistant Professor in the Pediatrics department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdolescentChild
Child, Preschool
Chimerism
Female
Hematopoietic Stem Cell Transplantation
Humans
Infant
Leukemia, Myeloid, Acute
Male
Myelodysplastic Syndromes
Neoplasm Recurrence, Local
Retrospective Studies
T-Lymphocytes
Transplantation Chimera
Young Adult
